Pre Existing condition Marfan Syndrome is the disease that will benefit the most from what Republicans calls Obama Care

February 25, 2011 By Robert Graham Reporting ---- Washington DC
at The National Press Club -----< Business--Wire>


Pre Existing condition Marfan Syndrome is the disease that
will benefit the most from what Republicans calls Obama Care

Speaking on what the Republicans Call "Obama Care" and When
is the best time to put your hat in the ring for a Presidential Election
at The National Press Club Hybrid Pharma ask what dose Mike Huckabee think about Marfan syndrome ?

The Marfan syndrome is a connective tissue disorder.
Connective tissue provides substance and support to tendons,
ligaments, blood vessel walls, cartilage, heart valves
and many other structures.

American Heart Association is concerned about Marfan Syndrome, in the UK
Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures.

The BioMatrix™ drug-eluting stent (DES) system was the first to be marketed anywhere in the world to feature an abluminally-coated biodegradable polymer incorporating the anti-restenotic drug Biolimus A9™, specifically developed by Biosensors for use in DES systems. The poly-lactic acid (PLA) polymer fully degrades into carbon dioxide and water over a six to nine month period as the drug elutes, ultimately leaving behind a bare-metal stent (BMS).

The latest version of BioMatrix, the BioMatrix Flex™, launched in Asia, Europe, the Middle East and Africa in May 2010, has the drug and polymer coated on a highly flexible platform designed to enhance deliverability.

Three-year results from the pivotal LEADERS study, presented at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in September 2010, suggested improved safety and efficacy of BioMatrix Flex over Cypher® Select™: there was a diverging trend towards a lower rate of MACE (major adverse cardiac events) in patients treated with BioMatrix Flex versus those treated with Cypher Select when compared to both one and two year results (15.7% vs. 19.0%; P value for superiority = 0.09). In the high-risk sub-group of STEMI (ST Elevation Myocardial Infarction) patients, there was a significant reduction in MACE rate for BioMatrix Flex compared to Cypher Select. Although this was an all-comers study, occurrence of very late stent thrombosis (VLST) events was low: a cumulative 0.2% for BioMatrix Flex out to three years, with no VLST events observed after two years.

BioFreedom™, a ‘next generation’ polymer-free drug-coated stent (DCS), is currently under clinical investigation. It features a micro-structured abluminal surface, which permits the controlled release of Biolimus A9 without the use of a polymer. 12-month results from the First-In-Man (“FIM”) trial were also presented at TCT in September 2010. They demonstrated equivalent efficacy, as measured by late lumen loss, for BioFreedom compared to Taxus® Liberté®, with a trend towards superiority. BioFreedom demonstrated sustained safety up to 12 months, including absence of stent thrombosis.

In the Marfan syndrome, the chemical makeup of the connective
tissue isn't normal. As a result, many of these structures
are not as stiff as they should be.

Hybrid Pharma Scientist say Marfan syndrome is caused by mutations in the FBN1 gene. FBN1 mutations are associated with a broad continuum of physical features ranging from isolated features
of Marfan syndrome to a severe and rapidly progressive
form in newborns.

Marfan syndrome is one of the most common inherited disorders
of connective tissue. It is an autosomal dominant condition

When the Marfan syndrome has been diagnosed, regular visits
with a cardiologist are needed.Chest X-rays and Doppler
echo tests are usually performed.

Hybrid Pharma say Marfan syndrome is a clinical diagnosis that
is based on family history and the presence of characteristic
clinical findings in ocular, skeletal and cardiovascular systems.
There are four major clinical diagnostic features:

1. Dilatation or dissection of the aorta at the level of the sinuses of Valsava.
2. Ectopia lentis (dislocated lens of the eye).
3. Lumbosacral dural ectasia determined by CT scan or magnetic resonance imaging (MRI).
4. Four of the eight typical skeletal features.

Genomics is a major criteria for establishing the diagnosis in a family member also include having a parent, child, or sibling who meets major criteria independently, the presence of an FBN-1 mutation known to cause the syndrome, when FBN-1 is inherited by descent and identified in a familial Marfan patient.

The FBN1 gene is the gene associated with the true Marfan syndrome. Genomic Genetic testing of the FBN1 gene identifies 70 - 93 percent of the mutations and is available in clinical laboratories. However patients negative for the test for gene mutation should be considered for evaluation for other conditions that have similar features of Marfan syndrome such as Dietz syndrome, Ehlers Danlos syndrome, and homocystinura.
To unequivocally establish the diagnosis in the absence of a family
history requires a major manifestation from two systems and involvement of a third system. If a mutation known to cause Marfan syndrome is identified, the diagnosis requires one major criterion and involvement of a second organ system.

Hybrid Parma Panoincell is a new technology that looks for the FBN1 gene.

Hybrid Pharma Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.


2011 National Marfan Foundation Grant Program for Researchers with Faculty Appointments

The National Marfan Foundation grant program for researchers with faculty appointments is designed to provide financial support for investigators studying any or all disciplines involved in the Marfan syndrome. Special areas of interest include cardiovascular, genetic, orthopedic and ophthalmologic issues of the Marfan syndrome and related disorders.

The National Marfan Foundation accepts applications on a yearly basis for one- or two-year grants in basic, translational or clinical research. Applications with budgets up to $50,000 per year for a total of $100,000 are acceptable. Grant awards are based on peer review by the NMF Scientific Advisory Board with the approval of the NMF Board of Directors.